`
Sad news.
See #241.
Zyesami (aka Aviptadil / RLF-100).
The FDA's decision on an Emergency Use Authorization should be coming in the next few days/weeks. It's already being used elsewhere on emergency use.
This is a patented formulation of Vasoactive Intestinal Polypeptide (VIP is naturally found in the body) and was initially being tested as a treatment for very serious covid cases, but other formulations are being tested on more mild cases. [2][3][4]
This therapeutic has a multimodal mechanism of action: decrease of inflammatory cytokines release leading to prevention of cytokine storm syndrome and viral replication, immunomodulating effect, vasodilating and bronchodilating effects, and prevention of surfactant depletion (surfactant coats the inside of the lungs, which can be lost during COVID-19 and lead to respiratory failure).
Information for those with critical covid in respiratory failure:
ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (SAMICARE)Patients with Critical COVID-19 and respiratory failure who are ineligible for enrollment in NCT04311697, who live more than 50 miles from an existing collaborating research center, or who are already hospitalized and cannot safely be transferred to a collaborating research facility may be considered for expanded access by the sponsor.
Treating physicians must complete FDA Form 3396 and receive a letter of authorization from NeuroRx, along with local IRB authorization.
Please refer to FDA guidance for Individual Patient Expanded Access https://www.fda.gov/media/91160/download
Now, if only Dr. Fraudchi et. al would get past their obsession with vaccines, and vaccines only...there are a number of great therapeutic candidates out there that could be of immense benefit to lowering the death rate from covid.